Blacksmith, Forge to merge for developing metalloenzymes-targeting drugs
Under the deal, both firms will use their combined chemistry platforms to create a biopharma that will develop…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
03 Jan 23
Under the deal, both firms will use their combined chemistry platforms to create a biopharma that will develop…
02 Jan 23
The Phase 3 study has met its primary endpoint of non-inferiority and superiority in the annualised bleeding rate…
29 Dec 22
As per the deal, PeptiDream will offer peptide candidates found from PeptiDream’s Peptide Discovery Platform System technology for…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
28 Dec 22
The deal includes the purchase of remaining financial obligations for anti-CCR8 antibody in development as part of Gilead's…
27 Dec 22
Under the agreement, Hikma will develop and commercialise toripalimab in all its MENA markets and will have the…
26 Dec 22
The approval was based on positive results from the phase II GO29781 study of Lunsumio which showed high…
23 Dec 22
Merck will obtain exclusive global licenses to research, develop, manufacture, and commercialise investigational preclinical ADC therapies, along with…
23 Dec 22
The approval is backed by data from the CAPELLA phase 2/3 trial which assessed Sunlenca in combination with…
22 Dec 22
Actemra is a humanised monoclonal antibody indicated for hospitalised adult patients receiving systemic corticosteroids and require supplemental oxygen,…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
22 Dec 22
The decision was based on positive results from the HERIZON-BTC-01 trial in previously treated HER2-amplified biliary tract cancers